• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Conclusion: The price of alirocumab would have to be reduced considerably to be cost-effective. Because substantial reductions already have occurred, we believe that timely, independent cost-effectiveness analyses can inform clinical and policy discussions of new drugs as they enter the market. Primary Funding Source: University of California, San Francisco, and Institute for Clinical and Economic Review. PMID: 30597485 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 1, 2019 Category: Internal Medicine Authors: Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K Tags: Ann Intern Med Source Type: research